Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7816058 | 0.90 | MAPK14 (0.51) | MAPK14USP2ALDH1A1CYP1A2TSHR | |
| SCHEMBL7811422 | 0.86 | MAPK14 (0.46) | MAPK14USP2ALDH1A1CYP1A2TSHR | |
| SCHEMBL6947830 | 0.81 | MAPK14 (0.60) | MAPK14 | |
| SCHEMBL4592699 | 0.80 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4584442 | 0.78 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK11TGFBR1 | |
| SCHEMBL6947142 | 0.77 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6948154 | 0.77 | MAPK14 (0.90) | MAPK14 | |
| SCHEMBL4984681 | 0.77 | MAPK14 (0.62) | MAPK14 | |
| SCHEMBL4985137 | 0.76 | MAPK14 (0.61) | MAPK14MAPK11 | |
| SCHEMBL4987749 | 0.76 | MAPK14 (0.58) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0996446-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | claimed |
| US-6562832-B1 | Cytokine suppressive anti-inflammatory drugs, capable of inhibiting the CSBP/p38/RK kinase | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | claimed |
| EP-0996446-A4 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-08-29 | — | — | EP | claimed |
| EP-0996446-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1999001131-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0996446-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6562832-B1 | Cytokine suppressive anti-inflammatory drugs, capable of inhibiting the CSBP/p38/RK kinase | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| US-6046208-A | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, ENDOTOXEMIA AND/OR TOXIC SHOCK SYNDROME, OTHER ACUTE OR CHRONIC INFLAMMATORY DISEASE STATES SUCH AS THE INFLAMMATORY REACTION INDUCED BY ENDOTOXIN OR INFLAMMATORY BOWEL DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |